GYNECOLOGIC CANCERS

An expert gynecologic oncologist discusses the rationale for using PD-L1 inhibitors and CTLA4 inhibitors in gynecologic cancers.

David M. O’Malley, MD, provides insight on the evolution of cervical cancer and reviews current systemic treatment options for recurrent and advanced disease.

Dana Chase, MD, discusses frontline therapy options for patients with advanced ovarian cancer.

he CINtec PLUS Cytology duel-stain biomarker technology was found to be more sensitive than Pap in detecting cervical precancer in women with HPV.

Even though most early stage adult patients with granulosa cell tumors experience an excellent outcome, up to 33% of patients will eventually develop a tumor relapse. Recurrence may be detected many years after the initial treatment, thus prolonged surveillance is necessary.

Pembrolizumab is now FDA approved in combination with chemotherapy and with or without bevacizumab, for the treatment of patients with persistent, recurrent or metastatic cervical cancer whose tumors express PD-L1.

The FDA has accepted and granted priority review to the supplemental biologics license application for the PD-1 inhibitor cemiplimab-wlc for the treatment of patients with recurrent or metastatic cervical cancer whose disease progressed on or after chemotherapy.

Tisotumab vedotin has become the first and only approved antibody-drug conjugate for the treatment of recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.

Tisotumab vedotin elicited significant responses without prohibitive toxicity in combination with carboplatin as frontline therapy, as well as in combination with pembrolizumab as second- or third-line therapy in patients with recurrent or metastatic cervical cancer.

In patients with persistent, recurrent, or metastatic cervical cancer the addition of pembrolizumab to chemotherapy with or without bevacizumab significantly improved survival and response rates.

High responses to single-agent dostarlimab-gxly were seen in patients with endometrial cancer who had a high tumor mutational burden, irrespective of mismatch repair or microsatellite stability status.

The first patient with a locally advanced or metastatic solid tumor has been dosed with buparlisib in combination with A0025 with or without atezolizumab in a phase 1a clinical trial.

In an interview with Targeted Oncology, Melissa K. Frey, MD, discussed findings from implementing web-based health information collection of family history in patients with gynecologic cancers.

In an interview with Targeted Oncology™, Isabelle Ray-Coquard, MD, PhD, discussed the NEOPEMBROV study in greater detail and the benefits of adding pembrolizumab to perioperative treatment for serous carcinoma deemed non-optimally resectable.

In an interview with Targeted Oncology™, Shannon N. Westin, MD, MPH, FACOG, discussed the need for the DUO-E trial in the endometrial cancer space and the unique patient population the study will evaluate.

Shannon Westin, MD, MPH, FACOG, a gynecologic oncologist at The University of Texas MD Anderson Cancer Center, discusses the use of durvalumab with or without olaparib for the treatment of endometrial cancers.

The FDA has accepted a new supplemental biologics license application for pembrolizumab, an anti-PD-1 therapy, as a single agent for the treatment of patients with advanced endometrial carcinoma that is microsatellite instability-high or mismatch repair deficient, who have diseased progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.

Following the success of a phase 1 study that showed its potential for accelerated FDA approval in the future, the WEE-1 inhibitor, ZN-c3 has been dosed for the first time in the newly launched phase 2 study, which is exploring the agent for the treatment of adult women with recurrent or persistent uterine serous carcinoma.

In an interview with Targeted Oncology™, Shannon N. Westin, MD, MPH, FACOG, discussed the DUO-E trial, its design, end points, and the need for novel endometrial cancer therapies. 

In an interview with Targeted Oncology, Bobbie J. Rimel, MD, discussed the phase 2 NRG-GY012 results and the next step for cediranib plus olaparib as treatment of recurrent or metastatic endometrial cancer.

In an interview with Targeted Oncology, Melissa M. Hardesty, MD, explained the state of gynecologic oncology treatment for rural patients in Alaska and how research is finding answers for improving clinical outcomes.

In an interview with Targeted Oncology, Bradley Monk, MD, FACCOG, FACS, discusses the OUTBACK trial, including the results, strengths, and challenges.

The FDA has approved the combination of lenvatinib and pembrolizumab for the treatment of patients with advanced endometrial cancer that is not microsatellite instability–high or mismatch repair deficient, who have disease progression following prior systemic treatment and who are not candidates for curative surgery or radiation.

In an interview with Targeted Oncology, Eugene Ahn, MD, reviewed the data from the uterine cancer cohort of the TAPUR study and explained the implications of the findings.